research Safety and compatibility of a new nourishing baby shampoo and tip to toe wash with stearic acid
The new baby shampoo and wash with stearic acid is safe and potentially effective for nourishing babies' skin.
Search
for
Sort by
Research
240-270 / 1000+ results research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Advancing Hair Loss Assessment in Alopecia Areata: The Mathematical Case for Centralised, Standardised Imaging
Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.
research 5% Minoxidil topical foam for men: Hair growth in millennials – a post hoc analysis
Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Profile analysis of adverse events after boron neutron capture therapy for head and neck cancer: a sub-analysis of the JHN002 study
Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research 5% Minoxidil topical foam on women: Menopause and other covariates
5% minoxidil foam effectively regrows hair in women, with postmenopausal women seeing the most improvement.
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Effects of testosterone replacement therapy on sexual interest, function, and behavior in HIV+ men
Testosterone replacement therapy significantly improved sexual interest and function in HIV+ men.
research Comparison of a Novel Silicone Gel Wound Dressing vs Bacitracin After Follicular Unit Extraction Hair Transplantation
The new silicone gel wound dressing may speed up early healing after hair transplant surgery compared to Bacitracin.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Biotechs target stagnant baldness market
New drug shows promise for better hair growth in baldness treatment.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Alopecia universalis treated with bone morphogenetic protein?
A man with alopecia universalis regrew hair temporarily after a bone treatment.
research Formulation and Evaluation of Dual Action Herbal Hair Serum Elixir
The herbal hair serum effectively reduces hair fall and dandruff using natural ingredients.
research Formulation and Evaluation of Dual Action Herbal Hair Serum Elixir
The herbal hair serum effectively reduces hair fall and dandruff using natural ingredients.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research Safety, tolerability, and PK of topical calcitriol formulation for treatment of chemotherapy-induced alopecia (CIA) in patients receiving taxane-based regimen: Final results.
Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research Anti-cancer properties of olive oil secoiridoid phenols: a systematic review of in vivo studies
Olive oil compounds may help prevent cancer in animals, but human results are mixed.
research The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models
AS101 reduces hair loss from chemotherapy.
research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Dutasteride
Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.